News

Experts regret early cessation of anticancer drug trial

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7420.885 (Published 16 October 2003) Cite this as: BMJ 2003;327:885
  1. Scott Gottlieb
  1. New York

    Treatment with the aromatase inhibitor letrozole after five years of tamoxifen treatment seems to improve disease-free survival in postmenopausal women with primary breast cancer.


    Embedded Image

    Study participant Kathy Anderson (left) and second author of the research paper Dr James Ingle of the Mayo Clinic in Rochester, Minnesota (right)

    Credit: AP PHOTO/AARON HARRIS

    The study, designed to test five years of letrozole treatment after tamoxifen therapy, was discontinued after a median follow up of only 2.4 years because the researchers observed survival benefit in the letrozole group compared with the placebo group. The study is scheduled to …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe